endo.digital Simplifies CGM Utilization: Yale Case Study

---

About DreaMed Diabetes

DreaMed Diabetes is a diabetes software company turning complex glucose and insulin data into expert-level treatment guidance. Built on more than a decade of clinical, algorithmic and regulatory experience, DreaMed develops FDA-cleared solutions that support insulin optimization for healthcare providers and patients. Its endo.digital platform brings decision support into clinical workflows, while MODI extends personalized, CGM-informed dose recommendations directly to eligible adults using insulin injections. For more information, visit www.dreamed.ai.